ADP-Induced Recalcified Blood Clotting Time as a Marker of Rethrombosis Risk and Effectiveness of Antiplatelet Therapy in Acute Coronary Syndrome

Kardiologiya - Russian Federation
doi 10.18087/cardio.2018.6.10128
Full Text
Abstract

Available in full text

Date
Authors
Publisher

APO Society of Specialists in Heart Failure

Related search

Antiplatelet Therapy in Acute Coronary Syndrome

Continuing Cardiology Education
2017English

The Underutilisation of Dual Antiplatelet Therapy in Acute Coronary Syndrome

International Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2019English

Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome

Annals of Internal Medicine
Internal MedicineMedicine
2014English

Old and New Players in Oral Antiplatelet Therapy in Treatment of Acute Coronary Syndrome

Nepal Journal of Medical Sciences
1970English

An Improved Plasma Recalcified Clotting Test and Its Modification as a Simple Rapid Heparin Retarded Clotting Test

Journal of Clinical Pathology
MedicineForensic MedicinePathology
1962English

Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2019English

Factors Associated With Platelet Reactivity During Dual Antiplatelet Therapy in Patients With Diabetes After Acute Coronary Syndrome

Scientific Reports
Multidisciplinary
2020English

Antiplatelet Treatment in Acute Coronary Syndrome Patients: Real-World Data From the START-Antiplatelet Italian Registry

PLoS ONE
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy